Truemag

  • Subscribe
    • New Subscription
    • Account Updates
    • Customer Service
  • News & Events
    • News
    • Events
  • Advertise
    • Media Kit
    • Reprints
    • Contacts
  • Editorial
    • Podcasts
    • Current Articles
    • Digital Editions
    • eNewsletter
    • Editor’s Desk
    • Edit Calendar
    • Contacts
  • Buyers Guide
    • Search
    • Sponsor Index
    • Vendor Update
  • Annual Software Ranking
    • Ranking Form
    • Annual Software Ranking
    • 2018 Software Ranking File Package

InveniAI’s Innovation Monitoring Platform, AlphaMeld, Witnesses Rapid Uptake in BioPharma and Adjacencies

10.22.18

InveniAI Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, today announced that since the launch of its AlphaMeld™ platform in early 2018, it has seen rapid adoption and interest not only across BioPharma, but also adjacencies such as Consumer Healthcare, Public Health/Vaccines, and Animal Therapeutics.
InveniAI seeks to make AlphaMeld the go-to platform for all innovative industries. The platform operates in real-time and seamlessly melds human expertise with powerful and optimized machine learning algorithms to identify signals of emerging innovation. With the commercial launch of AlphaMeld™ in Q1 2018, InveniAI has formed partnerships with large Pharma, Specialty Pharma, Biotech, Consumer Healthcare, and has numerous collaborations in advanced negotiations.

Krishnan Nandabalan, Ph.D., President and CEO, InveniAI Corporation said, “Anticipating the future and eliminating uncertainties is critical in shaping business strategy and driving corporate decisions. As we see the digital re-invention of industries, AlphaMeld brings both power and scale to decision-making and plugs a critical gap by engaging both internal experts and machine learning algorithms to identify emerging signals of innovation. Our collaborators are able to make both confident and early decisions using real-time insights specific to their organization’s needs.”

InveniAI continues to push the boundaries of AI and ML in all areas impacting R&D and productivity in BioPharma and is actively exploring adjacencies in other sectors to maximize the application of AlphaMeld. Collaborations are typically multiyear SaaS (Software-as-a-Service) deals.

www.inveniai.com

Oct 22, 2008Olivia Cahoon
Embratel Selects VMware to Deliver New Software-Defined WAN Services in BrazilBitnami Opens Flagship Product, Stacksmith, for Free Usage
Product Centrics
TrueNAS Open Source Storage Platform brings Full Windows ACL Support to Linux

Fully featured Windows file system ACLs are well supported in TrueNAS 12.0 (CORE and Enterprise), but not generally supported by Linux. Thanks to some innovation, and sweat from the iXsystems engineering team, TrueNAS SCALE 21.08...

Driving Successful Digital Transformation Initiatives in 2022

Well, the end of the year is the perfect time to reflect on all the past year's activities and plan for the coming year. As we plan for 2022, one thing...

Recovery Platforms

Established in 2013, Imanis Data, previously Talena...

Data Driven Efficiency

Founded in 2003, Tableau is a public software company...

Updated Hitachi CRM

Building Product Manufacturers (BPM) require...

Quick Links
Untitled Document
SW500 SW500 SW500 SW500 SW500
2022 © Rockport Custom Publishing, LLC